OrphAI Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
16
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$56.9M
OrphAI Therapeutics General Information
Description
Developer of a precision therapeutics technology designed to treat cancer and rare diseases. The company's technology accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics and combinational drug screening with deep learning to match clinical drugs, enabling doctors to treat diseases by providing significant therapeutic benefits for patients.
Contact Information
Website
www.orphai-therapeutics.comCorporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
Corporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
OrphAI Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 18-May-2026 | $56.9M | Completed | Clinical Trials - Phase 2 | ||
| 6. Later Stage VC (Series E) | 11-Oct-2024 | Completed | Clinical Trials - Phase 2 | |||
| 5. Debt - PPP | 03-May-2020 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series C) | 30-Mar-2017 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 03-Feb-2016 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 06-Jun-2013 | $20M | $20M | Completed | Clinical Trials - General | |
| 1. Accelerator/Incubator | Completed | Clinical Trials - General |
OrphAI Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 12,500,000 | $0.000100 | 8% | $0.8 | $0.8 | 1x | $0.8 | 5.58% |
| Series A | 25,250,000 | $0.000100 | 8% | $0.8 | $0.8 | 1x | $0.8 | 11.28% |
OrphAI Therapeutics Comparisons
Industry
Financing
Details
OrphAI Therapeutics Competitors (34)
One of OrphAI Therapeutics’s 34 competitors is Genentech, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Seragon | Formerly VC-backed | Irvine, CA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
OrphAI Therapeutics Patents
OrphAI Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11967436-B2 | Methods and apparatus for making biological predictions using a trained multi-modal statistical model | Active | 30-May-2018 | ||
| US-20200350081-A9 | Methods and apparatus for making biological predictions using a trained multi-modal statistical model | Active | 30-May-2018 | ||
| WO-2019067666-A1 | Therapeutic methods relating to hsp90 inhbitors | Inactive | 27-Sep-2017 | ||
| WO-2018144680-A1 | Methods for treating cancer using hsp90 inhibitors | Inactive | 03-Feb-2017 | ||
| WO-2018071548-A1 | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | Inactive | 12-Oct-2016 | A61K31/5377 |
OrphAI Therapeutics Signals
OrphAI Therapeutics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 4Catalyzer | Accelerator/Incubator | Minority | ||
| Albany Capital (Australia) | Venture Capital | Minority | ||
| Gravity Ventures (Korea) | Corporate Venture Capital | Minority | ||
| LifeSci Venture Partners | Corporate Venture Capital | Minority | ||
| Shenzhen Sangel Venture Capital | Venture Capital | Minority |
OrphAI Therapeutics FAQs
-
When was OrphAI Therapeutics founded?
OrphAI Therapeutics was founded in 2013.
-
Where is OrphAI Therapeutics headquartered?
OrphAI Therapeutics is headquartered in New Haven, CT.
-
What is the size of OrphAI Therapeutics?
OrphAI Therapeutics has 16 total employees.
-
What industry is OrphAI Therapeutics in?
OrphAI Therapeutics’s primary industry is Drug Discovery.
-
Is OrphAI Therapeutics a private or public company?
OrphAI Therapeutics is a Private company.
-
What is the current valuation of OrphAI Therapeutics?
The current valuation of OrphAI Therapeutics is .
-
What is OrphAI Therapeutics’s current revenue?
The current revenue for OrphAI Therapeutics is .
-
How much funding has OrphAI Therapeutics raised over time?
OrphAI Therapeutics has raised $154M.
-
Who are OrphAI Therapeutics’s investors?
4Catalyzer, Albany Capital (Australia), Gravity Ventures (Korea), LifeSci Venture Partners, and Shenzhen Sangel Venture Capital are 5 of 8 investors who have invested in OrphAI Therapeutics.
-
Who are OrphAI Therapeutics’s competitors?
Genentech, Seragon, Renova Therapeutics, Merck & Co., and Inovio Pharmaceuticals are some of the 34 competitors of OrphAI Therapeutics.
-
When was OrphAI Therapeutics acquired?
OrphAI Therapeutics was acquired on 18-May-2026.
-
Who acquired OrphAI Therapeutics?
OrphAI Therapeutics was acquired by IRulya Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process